A database of FDA approved therapeutic peptides and proteins
ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1403 | Th1065 | Digoxin Immune Fab (Ovine) | Heavy Chain: EVQLQQS Full view | 438 | IIa | Cardiac | DIGIBIND | Galaxo Smith Kline | Sterile lyophilized powder of antigen binding fragments (Fab) derived from specific antidigoxin antibodies raised in sheep. | Intravenous infusion after reconstitution with Sterile Water for Injection | Antidotes | T-cell surface glycoprotein CD3 delta chain, T-cell surface glycoprotein CD3 epsilon chain, T-cell surface glycoprotein CD3 gamma chain, T-cell surface glycoprotein CD3 zeta chain, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Complement C1s subcomponent, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c |
1404 | Th1065 | Digoxin Immune Fab (Ovine) | Heavy Chain: EVQLQQS Full view | 438 | IIa | Cardiac | DigiFab |  Protherics Inc | Sterile, purified, lyophilized preparation of digoxin-immune ovine Fab (monovalent) immunoglobulin fragments. | Intravenous administration | Antidotes | T-cell surface glycoprotein CD3 delta chain, T-cell surface glycoprotein CD3 epsilon chain, T-cell surface glycoprotein CD3 gamma chain, T-cell surface glycoprotein CD3 zeta chain, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Complement C1s subcomponent, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c |
1454 | Th1084 | Becaplermin | SLGSLTIAEPAMIAECKTRT Full view | 109 | Ib | Cardiac | REGRANEX | OMJ Pharmaceuticals, Inc. San German, Puerto Rico | Gel: 0.01 %; clear, colorless to straw-colored gel | External use only | Angiogenesis Inducing Agents | T-cell surface glycoprotein CD1a,Major histocompatibility complex class I-related gene protein,Integrin alpha-L,T-lymphocyte activation antigen CD86,Low affinity immunoglobulin gamma Fc region receptor II-b,T-cell surface glycoprotein CD4,Integrin beta-1,Integrin alpha-V,Integrin beta-3 |
1468 | Th1091 | Bevacizumab | DIQMTQSPSSLSASVGDRVT Full view | 214 | IIa | Cardiac | Avastin | Genentech | Slightly opalescent, colorless to pale brown, sterile, pH 6.2 solution for intravenous infusion | Intravenous infusion | Angiogenesis Inhibitors | Interleukin-2 receptor subunit alpha,Interleukin-2 receptor subunit beta,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
1530 | Th1109 | Nesiritide | SPKMVQGSGCFGRKMDRISS Full view | 32 | Ib | Cardiac | NATRECOR | Scios unit of Johnson & Johnson, | White- to off-white lyophilized powder | Intravenous injection | N.A. | N.A. |
1678 | Th1162 | Alirocumab | NA Full view | 0 | Ic | Metabolic/Cardiac | Praluent | Sanofi Aventis U.S. Llc | Injection, Solution | Subcutaneous | N.A. | Proprotein convertase subtilisin/kexin type 9 |
1679 | Th1162 | Alirocumab | NA Full view | 0 | Ic | Metabolic/Cardiac | Praluent | Sanofi Aventis Canada Inc | Solution | Subcutaneous | N.A. | Proprotein convertase subtilisin/kexin type 10 |
1680 | Th1162 | Alirocumab | NA Full view | 0 | Ic | Metabolic/Cardiac | Praluent | Sanofi Aventis Canada Inc | Solution | Subcutaneous | N.A. | Proprotein convertase subtilisin/kexin type 11 |
1681 | Th1162 | Alirocumab | NA Full view | 0 | Ic | Metabolic/Cardiac | Praluent | Sanofi Aventis U.S. Llc | Injection, Solution | Subcutaneous | N.A. | Proprotein convertase subtilisin/kexin type 14 |
1741 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | NA | NA | Injection, Solution; Injection | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 9 |
1742 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | Repatha | Amgen Inc | Injection, Solution | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 10 |
1743 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | Repatha | Amgen Canada Inc | Solution | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 11 |
1744 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | Repatha | Amgen Inc | Injection, Solution | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 12 |
1831 | Th1221 | C1 Esterase Inhibitor (Recombinant) | NA Full view | 0 | IIa | Cardiac Disorders | Ruconest | Tjoapack Netherlands Bv | Powder and liquid for solution | Intravenous | Blood and Blood Forming Organs | Complement C1r subcomponent, Complement C1s subcomponent, Plasma kallikrein, Coagulation factor XII, Prothrombin, Coagulation factor XI, Tissue-type plasminogen activator |